Skye Bioscience Inc（SKYE）股票分析SKYESkye Bioscience Inc

Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Skye Bioscience Inc is not a good buy right now due to significant financial losses and a very low RSI of 6.025, indicating extreme oversold conditions. The company reported a net loss of $14.4 million in Q4 2025, which is a substantial increase from the previous year, raising concerns about its operational viability. Additionally, the stock has seen a drastic decline of 93.44% over the past year, which suggests a lack of investor confidence and potential long-term viability issues.